BridgeMD
New treatment option for Temporal Lobe Epilepsy (TLE)
Official title MRgLITT for mTLE: A PROBE Trial
ClinicalTrials.gov ID: NCT06720922
What this study is testing
- What it's testing
- How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- 18-65 years.
- Drug-resistant mesial temporal lobe epilepsy.
- Seizure frequency ≥ 1 time /month.
- Participants approved.
You likely can't join if
- History of brain surgery.
- Intracranial space occupying lesions.
- Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease...
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.